Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
published in: Lancet Neurology
date of publication: 2017-10-20
language: English
main subject: myasthenia gravis, placebo
Cites articles 34
- 2016-09-01
- 2008-02-01
Date
Title
Article - wd:Q45070916